Blood testing market seen hitting $144.8 billion by 2031

Mordor Intelligence says the global blood testing market will grow from $103.53 billion in 2026 to $144.80 billion by 2031 as chronic disease screening, automation and point-of-care testing expand. North America remains the largest market, while Asia-Pacific is expected to grow fastest.

Why it matters: - Blood testing is becoming more central to chronic-disease management, preventive screening and decentralized care. - The market expansion points to rising demand for faster diagnostics, more automated lab workflows and testing closer to patients. - North America leads now, but Asia-Pacific is expected to post the fastest growth through 2031.

What happened: - Mordor Intelligence estimates the blood testing market at $103.53 billion in 2026. - The firm projects the market will reach $144.80 billion by 2031. - The forecast implies a 6.94% CAGR for 2026–2031. - The report says North America accounted for 43.6% of global revenue in 2025. - The report was published from Hyderabad, Telangana, India, on Oct. 6, 2026.

The details: - Rising rates of cardiovascular disease, diabetes, chronic kidney disease and other long-term conditions are driving recurring demand for blood panels. - Routine glucose, lipid, hemoglobin and kidney-function tests remain core tools for monitoring chronic disease and preventive care. - Government-funded screening programs and wider healthcare access are lifting testing volumes in developed and emerging markets. - Laboratories and providers are investing in automated analyzers, integrated chemistry-immunoassay platforms and point-of-care systems to speed turnaround times and improve workflow efficiency. - Automation is also helping labs manage shortages of trained personnel while supporting higher testing volumes. - Connected platforms and middleware are increasingly linking testing workflows with electronic health records and clinical decision-support systems. - Government-funded screening initiatives and expanded diagnostic infrastructure are creating new opportunities for blood testing providers. - Home microsampling, point-of-care analyzers, physician-office testing and retail diagnostic services are moving more testing away from central laboratories. - The report lists key test types including glucose, lipid panel, PSA, BUN, TSH, infectious-disease serology, vitamin D and high-sensitivity CRP. - The report covers instruments and consumables, plus clinical chemistry, molecular diagnostics and immunoassay technologies. - Diagnostic laboratories, hospitals and other care settings are the main end users.

Between the lines: - The market shift is not just about higher volumes. It is also about where testing happens, with more activity moving into decentralized settings. - The emphasis on integrated platforms suggests vendors are competing on workflow control, not just assay performance. - Competitive advantage is increasingly tied to automation, assay menus, regulatory compliance and the ability to support connected testing systems. - North America’s lead reflects mature infrastructure and high testing volumes, while Europe’s growth is shaped in part by compliance demands under the European In Vitro Diagnostic Regulation. - Asia-Pacific’s faster growth reflects expanding infrastructure, broader screening and rising chronic disease rates. - Roche’s CE Mark for its Elecsys IGRA TB blood test in July 2026 and Siemens Healthineers’ CE Mark for capillary testing on Atellica analyzers in July 2026 show the industry moving toward more automated and broader-use blood testing.

What's next: - Mordor Intelligence expects Asia-Pacific to be the fastest-growing region at a 8.54% CAGR during 2026–2031. - The report says continued investment in automation and point-of-care testing will keep supporting market development. - Further adoption of decentralized testing workflows is likely as home sampling, retail diagnostics and physician-office testing expand. - The company makes the full blood testing report available in multiple languages, including Japanese, French, German, Spanish and Portuguese: More information

The bottom line: - Blood testing is shifting from a routine lab function to a more automated, connected and decentralized diagnostics market with steady global growth through 2031.